The pharmaceutical industry adopted Big Tobacco's 'doubt is our product' playbook to suppress evidence of drug harms

When a 1969 internal memo from R.J. Reynolds tobacco executives surfaced decades later, it contained a phrase that would become infamous: "Doubt is our product since it is the best means of competing with the body of fact." The tobacco industry wasn't interested in proving their products were safe. They simply needed to muddy the waters enough to delay regulation and maintain sales. What seemed like a scandal contained within the tobacco industry turned out to be something far more consequential: a blueprint that would be adopted wholesale by an entirely different industry with the power to prescribe what millions of people ingest daily.

For years, critics who drew parallels between tobacco's disinformation tactics and pharmaceutical marketing were dismissed as conspiracy theorists making unfounded comparisons. The pharmaceutical industry argued that drugs undergo rigorous FDA approval and that marketing claims are heavily regulated. Critics were told they were conflating an industry that killed through deception with one that saved lives through science. It was a reasonable-sounding defense that most people accepted without question.

But the evidence tells a different story. When 30 million pages of tobacco documents were disclosed through litigation, researchers examining them began noticing something troubling. The tactics weren't unique to cigarettes. The same playbook—manufacturing scientific doubt, funding research designed to reach predetermined conclusions, creating apparent independence through third-party organizations, and cultivating relationships with medical professionals—started appearing in how pharmaceutical companies handled evidence of drug harms.

The opioid crisis provides the clearest example. Pharmaceutical companies minimized addiction risks for prescription painkillers through strategies that would have been instantly recognizable to a 1969 tobacco executive: downplaying internal research showing addiction potential, funding studies that questioned addiction concerns, and building relationships with doctors and patient advocacy groups to amplify messages of safety. Purdue Pharma's marketing campaign for , which claimed the drug had lower addiction rates than older painkillers despite internal knowledge suggesting otherwise, didn't emerge from a vacuum. It emerged from a template.